|
|
BX795 |
|
Vaxjo ID |
494 |
|
Vaccine Adjuvant Name |
BX795 |
|
Adjuvant VO ID |
VO_0005771
|
|
Description |
synthetic TBK1 inhibitor that leads to enhanced replication of viral vaccines |
|
Stage of Development |
Research |
|
Location Licensed |
Switzerland |
|
Function |
Type: synthetic vaccine adjuvant. BX795 interferes with antiviral signaling by inhibiting TANK-binding kinase 1 (TBK1), This inhibition of TBK1 leads to the suppression of type I interferon (IFN) signaling, which in turn allows for the replication of viral vaccines |
| References |
Sharma et al., 2020: Sharma S, Schmid MA, Sanchez Felipe L, Grenelle J, Kaptein SJF, Coelmont L, Neyts J, Dallmeier K. Small-molecule inhibitors of TBK1 serve as an adjuvant for a plasmid-launched live-attenuated yellow fever vaccine. Human vaccines & immunotherapeutics. 2020; 16(9); 2196-2203. [PubMed: 32574095].
|
|
